Analytical performance of a new chemiluminescent phenytoin (ACS:180) assay

Therapeutic Drug Monitoring

Volumn 19, Issue 2, 1997, Pages 191-194

  Dasgupta, Amitava ^a,c   Datta, Pradip ^b   Redlich, Gillian ^a   Limmany, Anicia ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b Ciba Corning Diagnostics Corp   (United States)

^c UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

ACS phenytoin; Fluorescence polarization

Indexed keywords

PHENYTOIN;

ACCURACY; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DILUTION; DRUG DETERMINATION; DRUG MONITORING; FLUORESCENCE POLARIZATION; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; LIVER DISEASE; PRIORITY JOURNAL; SERUM;

FLUORESCENCE POLARIZATION; HUMANS; PHENYTOIN;

EID: 0031470312     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199704000-00013     Document Type: Article

References (13)

1. Putman TJ, Merritt HH. Experimental determination of anticonvulsant properties of some phenyl derivatives. Science 1937;85:525-6.
2. Merritt HH, Putman TJ. Sodium diphenylhydantoinate in treatment of convulsive disorders. JAMA 1938;111:1068-73.
3. Toman JEP, Loewe S, Goodman LS. Physiology and therapy of convulsive disorders. I. Effect of anticonvulsant drugs on electroshock seizures in man. Arch Neurol Psychiatry 1947; 58:312-24.
4. Ayala GF, Johnston D. The influence of phenytoin on the fundamental electrical properties of simple neural system. Epilepsia 1977;18:299-307.
5. Delgado-Escueta AV, Horan MP. Phenytoin: biochemical membrane study. In: Glaser GH, Penry JK, Woodbury DM, eds. Antiepileptic drugs: mechanism of action. Advances in Neurology, vol. 27. New York: Raven Press, 1980:377-98.
6. Melikian AP, Straughn AB, Slywka GWA, Whyatt PL, Meyer MC. Bioavailability of 11 phenytoin products. J Pharmacokinet Biopharm 1977;5:133-46.
7. Theodore WH, Qu ZP, Tsay JY. Phenytoin: the pseudo steady-state phenomenon. Clin Pharmacol Ther 1984;35:822-5.
8. Mullen PW. Optimal phenytoin therapy: a new technique for individualizing dosage. Clin Pharmacol Ther 1978;23:228-32.
9. Wilder BJ, Serrano EE, Ramsay RE. Plasma diphenylhydantoin levels after loading and maintenance doses. Clin Pharmacol Ther 1973;14:798-801.
10. Burni J. Phenytoin. In: Taylor WJ, Diers Caviness MH, eds. A text book for the clinical application of therapeutic drug monitoring. Irvine,TX: Abbott Laboratories Diagnostics Division, 1986:253-67.
11. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-69.
12. Haidukewych D, Rodin EA. Serial free and plasma valproic acid and phenytoin monitoring and drug interactions. Ther Drug Monit 1981;3:303-7.
13. Miller JJ, Straub RW, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther Drug Monit 1996;18:65-72.